Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...
Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...
Stockhead on MSN16h
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agentBrazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...
Detailed price information for Telix Pharmaceutical Ltd (TLPPF) from The Globe and Mail including charting and trades.
It’s a brave call given the recent market sell-off, but the ASX’s ‘milestone’ moment represents a structural change.
(MENAFN- GlobeNewsWire - Nasdaq) MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces ...
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, ...
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX , Telix, the Company) today announces that it has developed and validated ...
TLX opened at $17.30 on Friday. The firm’s fifty day simple moving average is $17.47. Telix Pharmaceuticals Limited American Depositary Shares has a 52-week low of $14.01 and a 52-week high of $30.36.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback